Harmony Biosciences Holdings (Harmony Biosciences Holdings) Price-to-Operating-Cash-Flow : 8.02 (As of Apr. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Price-to-Operating-Cash-Flow?

As of today (2024-04-30), Harmony Biosciences Holdings's share price is $29.25. Harmony Biosciences Holdings's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.65. Hence, Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow Ratio for today is 8.02.

The historical rank and industry rank for Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow or its related term are showing as below:

HRMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.91 Med: 22.08 Max: 625.78
Current: 8.06

During the past 6 years, Harmony Biosciences Holdings's highest Price-to-Operating-Cash-Flow Ratio was 625.78. The lowest was 6.91. And the median was 22.08.

HRMY's Price-to-Operating-Cash-Flow is ranked better than
86.32% of 285 companies
in the Biotechnology industry
Industry Median: 24.83 vs HRMY: 8.06

Harmony Biosciences Holdings's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $1.30. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.65.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Harmony Biosciences Holdings was 53.70% per year.

Harmony Biosciences Holdings Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings Price-to-Operating-Cash-Flow Chart

Harmony Biosciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

25.61

23.30

8.89

Harmony Biosciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															23.30	12.64	13.33	11.80	8.89

Competitive Comparison of Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow falls into.

Harmony Biosciences Holdings Price-to-Operating-Cash-Flow Calculation

Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	29.25	/	3.649
	=	8.02

Harmony Biosciences Holdings's Share Price of today is $29.25.
Harmony Biosciences Holdings's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.65.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Harmony Biosciences Holdings Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Harmony Biosciences Holdings (Harmony Biosciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462

Website

https://www.harmonybiosciences.com

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Executives

Peter Anastasiou	director	C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andreas Wicki	director	C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Andrew Serafin	officer: Chief Business Officer	630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno	officer: Chief Medical Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Jeffrey Dierks	officer: Chief Commercial Officer	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
John C Jacobs	director, officer: President, CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Sandip Kapadia	officer: Chief Financial Officer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
R. Mark Graf	director	C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Eric L Motley	director	1516 33RD STREET NW, WASHINGTON DC 20007
Valor Equity Partners Iv-a L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Valor Equity Partners Iv-b L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Marshman Fund Trust Ii	10 percent owner	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Equity Capital Iv Llc	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611